Boehringer Ingelheim’s Micardis reaches 50m patient-years of experience

Boehringer Ingelheim has announced that its drug Micardis has reached 50 million patient-years of real world experience, 15 years since its approval in the US.

The represents a significant milestone and reflects the global value of the therapy in providing effective and well-tolerated 24-hour blood pressure control to patients with hypertension, meaning clinicians can prescribe the drug with confidence.

Micardis remains the only angiotensin II receptor blocker proven to achieve cardiovascular prevention beyond blood pressure lowering in a broad range of cardiovascular high-risk patients.

The therapy is also available as part of combination products such as MicardisPlus and Twynsta, which are intended for patients who need two or more antihypertensive agents to effectively control blood pressure, especially those with comorbidities.

Professor Klaus Dugi, corporate senior vice-president for medicine at Boehringer Ingelheim, said: "We are proud to have established a valued and widely prescribed portfolio of treatments that effectively treat a broad range of patients with such a prevalent condition."

This comes after the company announced positive clinical data earlier this month for Trajenta, the diabetes therapy it has developed alongside Lilly.